Machine learning (ML) approaches have been widely adopted within the early stages of the drug discovery process, particularly within the context of small-molecule drug candidates. Despite this, the use of ML is still limited in the pharmacokinetic/pharmacodynamic (PK/PD) application space. Here, we describe recent progress and the role of ML used in preclinical drug discovery. We summarize the advances and current strategies used to predict ADME (absorption, distribution, metabolism and, excretion) properties of small molecules based on their structures, and predict structures based on the desired properties for molecular screening and optimization. Finally, we discuss the use of ML to predict PK to rank the ability of drug candidates to achieve appropriate exposures and hence provide important insights into safety and efficacy.
Accurate prediction of new compounds' pharmacokinetic (PK) profile in humans is crucial for drug discovery. Traditional methods, including allometric scaling and mechanistic modeling, rely on parameters from in vitro or in vivo testing, which are labor-intensive and involve ethical concerns. This study leverages machine learning (ML) to overcome these limitations by developing data-driven models. We compiled a large data set of small molecules' physicochemical and PK properties from public sources and digitized human plasma concentration-time profiles for approximately 800 compounds from the literature. We introduced a hybrid modeling framework that combines ML with physiologically based pharmacokinetic modeling and a hierarchical ML framework that employs two steps of learning to directly estimate PK profiles. Tested on 106 drugs, these frameworks demonstrated prediction accuracies within a 2-fold and 5-fold error for 40-60% and 80%-90% of compounds, respectively, in both AUC and Cmax. Proposed approaches could enhance early molecular screening and design, advancing drug discovery capabilities.
Accurate prediction of a new compound's pharmacokinetic (PK) profile is pivotal for the success of drug discovery programs. An initial assessment of PK in preclinical species and humans is typically performed through allometric scaling and mathematical modeling. These methods use parameters estimated from in vitro or in vivo experiments, which although helpful for an initial estimation, require extensive animal experiments. Furthermore, mathematical models are limited by the mechanistic underpinning of the drugs' absorption, distribution, metabolism, and elimination (ADME) which are largely unknown in the early stages of drug discovery. In this work, we propose a novel methodology in which concentration versus time profile of small molecules in rats is directly predicted by machine learning (ML) using structure‐driven molecular properties as input and thus mitigating the need for animal experimentation. The proposed framework initially predicts ADME properties based on molecular structure and then uses them as input to a ML model to predict the PK profile. For the compounds tested, our results demonstrate that PK profiles can be adequately predicted using the proposed algorithm, especially for compounds with Tanimoto score greater than 0.5, the average mean absolute percentage error between predicted PK profile and observed PK profile data was found to be less than 150%. The suggested framework aims to facilitate PK predictions and thus support molecular screening and design earlier in the drug discovery process.
1 November 2018 in Progress in Biophysics and Molecular Biology
The idea of using a wing in ground effect vehicle has been suggested with the objective of developing a very economical and efficient means of rapid transportation across water bodies. This paper investigates into wing in ground effect airfoil geometry. ANSYS is used to perform the CFD analysis of the airfoils. CFD analysis has been performed on various airfoils operating in the ground effect region and a special class of airfoil called DHMTU has been found to have maximum aerodynamic efficiency. The DHMTU studied here is DHMTU 8-40-2-10-3-6-2-15. Aerodynamic efficiency for this particular airfoil has been determined through CFD analysis at various angles of attack. It has been found that the DHMTU possesses superior aerodynamic efficiency at low angle of attack and the maximum aerodynamic efficiency is found at 60 angle of attack. From CFD analysis it has also been determined that as the proximity to the ground reduces, the value of lift increases. The characteristics of this airfoil at various air speeds have also been determined through CFD analysis. These studies have illustrated the unique characteristics of the DHMTU airfoils and indicated areas for further optimization of the design of ground effect airfoils. The use of this airfoil for the ground effect vehicle can further lead to increase in efficiency of the craft. Abbreviations: CFD Computational Fluid Dynamics DHMTU Department Of Hydro-Mechanics of the Marine Technical University NACA National Advisory Committee on Aeronautics L/D Lift to Drag Ratio WIG Wing in Ground V Free stream velocity Re Reynolds number h/c Height to Chord Ratio CL Coefficient of lift CD Coefficient of drag AOA Angle Of Attack
With nearly 90% of drug candidates failing in clinical trials due to poor efficacy or toxicity, drug repurposing has emerged as a vital strategy to accelerate the delivery of life-saving treatments. However, most current drug repurposing approaches fail to account for the physiological barriers and downstream biological impacts that dictate therapeutic success. To bridge this gap, we present SCOUT (Screening Candidates via Organ Uptake and Target-binding), a modular machine learning-driven framework for drug repurposing by simultaneously modeling organ permeability, drug-target binding, and biomarker modulation. Unlike conventional repurposing efforts that rely on single-point predictions or disconnected steps, SCOUT integrates these factors into a unified predictive funnel, significantly reducing trial-and-error and prioritizing candidates with the highest probability of therapeutic relevance. As a proof of concept, we applied SCOUT to Alzheimer’s disease, where blood-brain barrier (BBB) penetration is an important hurdle. The framework first predicts the unbound brain-to-plasma partition coefficient, Kpuu, using SMILES-based embeddings and achieved robust performance (Accuracy: 0.90, Recall: 0.94), then integrates machine learning to predict binding affinity with BACE1, a key Alzheimer’s target that was used in this work as a proof of concept. By combining these modules, SCOUT reduced the candidate search space by 99.9% and identified hits with diverse mechanisms of action. Critically, SCOUT extends beyond hit identification by employing mechanistic modeling to simulate how these candidates might modulate specific disease biomarkers (e.g. Amyloid-beta (Aβ) peptides). This hybrid approach ensures repurposed candidates are not only chemically viable but also physiologically active, providing a rational and resource-efficient pipeline for drug development.